You've probably heard about gene editing to create hybrid species or designer babies. But what about its purpose to aid the wellbeing of humanity? Today, we're joined by Ian Karp on behalf of Intellia Therapeutics, a biotechnology company employing CRISPR-based gene editing to develop curative therapeutics for cancer and autoimmune disease. Tune in to hear his thoughts on recent clinical trial updates, how to effectively communicate the purpose of these therapies with the public, and what it's like to be at the forefront of medical innovation when it comes to gene editing.
Check out the work that Intellia is doing: www.intelliatx.com/
Ian Karp is a Senior Vice President at Intellia Therapeutics. He has over 25 years of expertise in the biopharmaceutical industry for investor relations, corporate communications, business development, and product commercialization.